Free Trial

Petros Pharmaceuticals (PTPI) Competitors

Petros Pharmaceuticals logo
$0.02 0.00 (-2.97%)
As of 03:53 PM Eastern

PTPI vs. ARTL, PRFX, CERO, GTBP, PWUP, VCNX, GLMD, SPRC, SLRX, and PTIX

Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Artelo Biosciences (ARTL), PainReform (PRFX), CERo Therapeutics (CERO), GT Biopharma (GTBP), PowerUp Acquisition (PWUP), Vaccinex (VCNX), Galmed Pharmaceuticals (GLMD), SciSparc (SPRC), Salarius Pharmaceuticals (SLRX), and Atrinsic (PTIX). These companies are all part of the "pharmaceutical products" industry.

Petros Pharmaceuticals vs. Its Competitors

Petros Pharmaceuticals (NASDAQ:PTPI) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Artelo Biosciences had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Artelo Biosciences and 0 mentions for Petros Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.50 indicating that Petros Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Petros Pharmaceuticals Neutral
Artelo Biosciences Negative

Petros Pharmaceuticals has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Petros Pharmaceuticals' return on equity of -78.22% beat Artelo Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Petros PharmaceuticalsN/A -78.22% -23.50%
Artelo Biosciences N/A -497.68%-213.76%

Artelo Biosciences has a consensus price target of $24.00, suggesting a potential upside of 610.06%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Petros Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Artelo Biosciences
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40

Petros Pharmaceuticals has higher revenue and earnings than Artelo Biosciences. Artelo Biosciences is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Petros Pharmaceuticals$5.11M0.12-$8.16M-$52.910.00
Artelo BiosciencesN/AN/A-$9.83M-$19.05-0.18

Summary

Petros Pharmaceuticals beats Artelo Biosciences on 9 of the 15 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTPI vs. The Competition

MetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$629K$1.03B$6.18B$10.67B
Dividend YieldN/A4.84%5.72%4.86%
P/E Ratio0.001.2629.0927.12
Price / Sales0.1230.41584.14126.40
Price / CashN/A17.6337.1261.42
Price / Book0.007.7812.246.43
Net Income-$8.16M-$8.09M$3.33B$276.63M
7 Day PerformanceN/A2.04%-1.46%-2.60%
1 Month PerformanceN/A26.01%5.03%0.31%
1 Year PerformanceN/A-14.40%61.45%30.63%

Petros Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTPI
Petros Pharmaceuticals
N/A$0.02
-3.0%
N/A-99.8%$629K$5.11M0.0020Gap Down
ARTL
Artelo Biosciences
2.2196 of 5 stars
$3.65
-6.1%
$24.00
+558.4%
-53.6%$2.55MN/A-0.195Short Interest ↑
PRFX
PainReform
0.9653 of 5 stars
$1.27
-1.9%
N/A-56.8%$2.54MN/A-0.014
CERO
CERo Therapeutics
3.5892 of 5 stars
$2.07
-13.8%
$45.00
+2,073.9%
-98.8%$2.53MN/A0.008News Coverage
Analyst Forecast
Short Interest ↓
Gap Up
GTBP
GT Biopharma
2.0004 of 5 stars
$0.70
-3.8%
$11.00
+1,467.0%
-71.1%$2.50MN/A-0.178
PWUP
PowerUp Acquisition
N/A$0.32
-7.5%
N/A-97.6%$2.45MN/A0.00N/AGap Down
High Trading Volume
VCNX
Vaccinex
0.8625 of 5 stars
$0.91
-5.7%
N/A-66.0%$2.38M$388K-0.0240News Coverage
Gap Down
GLMD
Galmed Pharmaceuticals
2.2817 of 5 stars
$1.44
+1.4%
N/A-69.4%$2.38MN/A-0.0920Positive News
SPRC
SciSparc
0.4104 of 5 stars
$4.26
-1.2%
N/A-30.2%$2.28M$1.31M0.004
SLRX
Salarius Pharmaceuticals
0.1742 of 5 stars
$3.81
-5.9%
N/A-86.2%$1.94MN/A-0.0920Negative News
Short Interest ↑
PTIX
Atrinsic
0.2033 of 5 stars
$3.16
-1.6%
N/A-68.2%$1.86MN/A-0.332

Related Companies and Tools


This page (NASDAQ:PTPI) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners